Antikoagulansbehandling skal overvåges nøje hos patienter, der får warfarin eller lignende præparater, idet det er vist, at galdesyrebindende præparater, såsom Cholestagel, reducerer optagelsen af vitamin K og derfor påvirker warfarins koagulationshæmmende virkning (se også punkt 4. 5).
Anticoagulant therapy should be monitored closely in patients receiving warfarin or similar agents, since bile acid sequestrants, like Cholestagel, have been shown to reduce absorption of vitamin K and therefore interfere with warfarin’ s anticoagulant effect (see also section 4.5).